AnalystBro Research
Research
Company valuation reports, peer comparisons, results notes, industry reports and macro views, built from company filings and official data and independently reviewed before publishing. Company reports show their full model as view-only sheets. Facts and estimates, not investment advice.
9 articles.
Company · DSE:TRUSTBANK · Banks · Analysis · 31 Oct 2026
Trust Bank: net interest income fell to 0.9% of earning assets in 2025 and to BDT 317m in H1 2026, while treasury income and a BDT 27.5bn special-mention book grew
Trust Bank's reported classified-loan ratio fell from 6.36% to 4.39% in 2025, but the bank wrote off BDT 10.9bn, special-mention loans rose from BDT 7.2bn to BDT 27.5bn, and the auditor says a significant proportion of classified borrowers were reported as unclassified after special rescheduling. Interest paid took 89% of interest income in 2025 and 98% in H1 2026; government securities and their income now carry the bank. Consolidated CRAR is 12.76% against 12.5% required.
Company · DSE:IFIC · Banks · Analysis · 31 Oct 2026
IFIC Bank: 61% of loans classified, a BDT 216bn provision shortfall (our sum of notes) deferred by Bangladesh Bank, CRAR of 1.8% and negative equity by June 2026
Loans tied to the old sponsor era turned bad in 2024. Interest on those loans has since moved to suspense, so net interest income fell to BDT -22.1bn in 2025 and to BDT -15.4bn in H1 2026. Book equity of BDT 5.7bn at Dec-2025 sits against a provision gap of BDT 215.9bn (our sum of four notes) that BB has allowed the bank to defer.
Company · DSE:SUNLIFEINS · Life insurance · Analysis · 29 Oct 2026
Sunlife Insurance: gross premium of BDT 186.7m in 2025 and a life fund of BDT 533.7m, both the lowest of seven years
Gross premium fell 21.5% in 2025 after a 69.5% fall in 2024. The life fund was BDT 533.7m at Dec-2025 and BDT 469.4m at Sep-2026 (DSE-announced). The auditor's report carries three emphasis of matter paragraphs and states the opinion is not modified; the board recommended no dividend for 2025.
Company · DSE:SONALILIFE · Life insurance · Analysis · 29 Oct 2026
Sonali Life Insurance: a young life fund of BDT 9.0bn now paying out maturities of BDT 2.9bn a year, with BDT 1.1bn of legacy receivables in court
Gross premium rose 8.3% to BDT 8.66bn in 2025 and the life fund grew 11.3% to BDT 8.96bn, but maturity claims reached BDT 2.86bn and the fund fell by BDT 40.0m in Q3 2026. BDT 5.31bn sits in one product with five banks, BDT 3.89bn of it at one bank. A BDT 1,098.4m receivable from before 2023 is unreconciled and under legal recovery.
Company · DSE:ONEBANKPLC · Banks · Analysis · 29 Oct 2026
ONE Bank: a 19.6% NPL bank whose Tk3,903 crore deferred provision is larger than its equity, with net interest income down to 0.9% of earning assets
Bangladesh Bank let ONE Bank defer Tk3,903 crore of required provisions for 2025. Without that permission the auditor says equity would be minus Tk1,025 crore. Classified loans have risen from 5.3% to 19.6% of loans since 2017, the cost of fund is 10.06%, CRAR is 11.12% against a 12.5% requirement, and the shares are in the Z category after a second year without a dividend.
Company · DSE:DELTALIFE · Life insurance · Analysis · 29 Oct 2026
Delta Life Insurance: a BDT 40.7bn life fund that went nowhere for five years, eight straight years of negative operating cash flow, and EPS that doubled to BDT 8.64
Gross premium rose 7.9% to BDT 10.2bn in 2025 and the life fund grew for the first time since 2020, after a regulator-appointed administrator ran the company from February 2021 to September 2022. A third of invested assets sit in listed shares. The stock trades at 8.0x FY2025 EPS with a 5.1% cash yield.
Company · DSE:NBL · Banks · Analysis · 29 Oct 2026
National Bank: 59.7% of loans classified, a Tk18,608 crore provision gap deferred by Bangladesh Bank and CRAR of -5.48%
National Bank lost BDT 24.3bn in 2025 and BDT 22.9bn more in H1 2026. Equity is negative, interest paid is 5x interest earned, deposits are 28% below their 2021 level, and the bank runs on Bangladesh Bank-backed liquidity. This note sets out the filings.
Company · DSE:BEXIMCO · Conglomerate · Analysis · 29 Oct 2026
Beximco Ltd: no accounts since December 2024, factories shut and Tk 87bn of parent debt
Beximco Ltd's last statement shows H1 FY2025 revenue down 71% and a Tk 3,565m loss. Six reporting periods are overdue, and the share has fallen 82% since its floor was removed.
Company · DSE:BXPHARMA · Pharmaceuticals · Initiation · 29 Oct 2026
Beximco Pharmaceuticals: fair value BDT 99–218 as FY2026 EPS rises 30% to BDT 20.17
Fair value BDT 99–218 (base 179) against a price of BDT 143.7. Domestic brands, exports and a falling materials bill lift EPS to BDT 28.7 by FY2029F; governance volatility (beta 1.46) and a weaker taka are the risks.
Fair value ৳99–218 · price ৳143.70 (2026-10-29)